C4 Therapeutics, Inc. SEC Filings

C4 Therapeutics Director Owen Hughes received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:

• Granted 35,500 stock options to purchase common stock
• Exercise price set at $1.44 per share
• Options expire on June 17, 2035
• Vesting schedule: Full vesting upon earlier of June 18, 2026 or next annual stockholder meeting

This Form 4 filing indicates standard board compensation practices through equity grants. The vesting conditions require continued service as a board member, aligning the director's interests with long-term shareholder value. The transaction was executed under direct ownership, with attorney Jolie M. Siegel signing as the authorized representative.

C4 Therapeutics director Stephen Fawell received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:

• Grant of 35,500 stock options to purchase common stock
• Exercise price set at $1.44 per share
• Options expire on June 17, 2035
• Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting

This Form 4 filing indicates standard board compensation practices through equity grants. The vesting structure aligns with typical director compensation arrangements, requiring continued board service. The relatively low exercise price suggests the company's stock may have experienced recent price declines, as C4 Therapeutics focuses on targeted protein degradation for treating cancer and other diseases.

C4 Therapeutics director Kenneth Carl Anderson received a stock option grant on June 18, 2025. The derivative security details include:

• Granted 35,500 stock options to purchase common stock
• Exercise price set at $1.44 per share
• Options expire on June 17, 2035
• Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting

The grant represents standard director compensation, with vesting contingent on continued board service. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025. This Form 4 disclosure complies with SEC requirements for reporting changes in beneficial ownership by company insiders.

C4 Therapeutics (NASDAQ:CCCC) filed a routine Form 4 on June 28, 2025, reporting that director Laura Bessen received a grant of 35,500 stock options on June 18, 2025 at an exercise price of $1.44 per share.

The options vest in full on the earlier of June 18, 2026 or the company’s next annual stockholder meeting, provided she remains on the board. No shares were sold, and the transaction reflects standard board compensation rather than an open-market trade. After the grant, Bessen directly holds 35,500 derivative securities.

C4 Therapeutics director Donna Roy Grogan received a stock option grant on June 18, 2025, as reported in a Form 4 filing. The derivative securities transaction details include:

• Grant of 35,500 stock options to purchase common stock
• Exercise price set at $1.44 per share
• Options expire on June 17, 2035
• Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting

The options are subject to continued service as a board member. This grant represents standard non-employee director compensation. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025.

C4 Therapeutics Director Steven L. Hoerter received a stock option grant on June 18, 2025 to purchase 35,500 shares of common stock at an exercise price of $1.44 per share.

Key details of the stock option:

• The option expires on June 17, 2035
• Vesting occurs at the earlier of June 18, 2026 or the next annual stockholders' meeting
• Vesting is contingent on continued Board service
• The grant was reported via Form 4 filing, indicating changes in beneficial ownership

This equity compensation aligns with standard director compensation practices and serves to align the director's interests with shareholders. The relatively low exercise price reflects the company's current market conditions.

C4 Therapeutics, Inc. (NASDAQ: CCCC) filed an 8-K to disclose the results of its 18 June 2025 Annual Meeting and a charter amendment. Stockholders approved doubling the Company’s authorized common shares to 300 million, effective upon the same-day filing of a Certificate of Amendment with the Delaware Secretary of State. This change provides the Board added flexibility for future equity-based financing, M&A currency, and incentive plans, but also increases potential dilution for existing holders.

All three Class II directors—Ronald Harold Wilfred Cooper, Donna Grogan, M.D., and Steven Hoerter—were re-elected for terms expiring at the 2028 annual meeting. Vote support ranged from 79.0 % to 99.6 % of shares cast, with sizeable broker non-votes (10.5 million shares).

Shareholders delivered strong (≈97.6 %) advisory approval of named executive officer (NEO) compensation. KPMG LLP was ratified as independent auditor for fiscal 2025 with 99.7 % support. The share-increase proposal passed with 65.7 % “For” (39.5 million vs 20.7 million “Against”), indicating some concern among holders about dilution. No other matters were presented, and no financial results were reported.